Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$191.51 - $216.16 $383 - $432
2 Added 3.23%
64 $14,000
Q2 2023

Jul 31, 2023

SELL
$187.64 - $206.25 $15,011 - $16,500
-80 Reduced 56.34%
62 $12,000
Q1 2023

Apr 26, 2023

SELL
$127.59 - $203.08 $3,700 - $5,889
-29 Reduced 16.96%
142 $29,000
Q4 2022

Jan 12, 2023

SELL
$117.37 - $139.17 $117 - $139
-1 Reduced 0.58%
171 $22,000
Q3 2022

Nov 08, 2022

BUY
$135.27 - $180.11 $6,492 - $8,645
48 Added 38.71%
172 $23,000
Q2 2022

Jul 15, 2022

BUY
$108.81 - $179.33 $4,896 - $8,069
45 Added 56.96%
124 $22,000
Q1 2022

May 06, 2022

SELL
$119.61 - $157.85 $2,272 - $2,999
-19 Reduced 19.39%
79 $11,000
Q4 2021

Feb 11, 2022

SELL
$142.57 - $190.86 $142 - $190
-1 Reduced 1.01%
98 $15,000
Q3 2021

Nov 10, 2021

BUY
$142.45 - $169.82 $2,564 - $3,056
18 Added 22.22%
99 $17,000
Q2 2021

Aug 02, 2021

BUY
$135.08 - $161.1 $3,512 - $4,188
26 Added 47.27%
81 $13,000
Q1 2021

May 07, 2021

BUY
$137.51 - $190.8 $7,563 - $10,494
55 New
55 $8,000

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Valley National Advisers Inc Portfolio

Follow Valley National Advisers Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valley National Advisers Inc, based on Form 13F filings with the SEC.

News

Stay updated on Valley National Advisers Inc with notifications on news.